There is a growing demand for the development of experimental strategies for efficient articular cartilage repair. Current tissue engineering-based regenerative strategies make use of human mesenchymal stromal cells (hMSCs). However, when implanted in a cartilage defect, control of hMSCs differentiation towards the chondrogenic lineage remains a significant challenge. We have recently demonstrated that silencing the anti-chondrogenic regulator microRNA-221 (miR-221) was highly effective in promoting in vitro chondrogenesis of monolayered hMSCs in the absence of the chondrogenic induction factor TGF-β.
INTRODUCTION
Adult articular cartilage does not heal spontaneously after injury and surgical repair remains a significant clinical challenge with few and sub-optimal therapeutic options [1] . Mesenchymal stromal cells (hMSCs) have been identified as an attractive cell source for cartilage regeneration due to their chondrogenic potential [2] [3] [4] [5] . Many studies demonstrating that cartilage tissue can be created from hMSCs have paid special attention to growth factors that are involved in promoting chondrogenesis. These growth factors, particularly the members of the transforming growth factor beta (TGF-β) family, induce hMSCs to acquire a chondrogenic phenotype, and synthesize specific extracellular matrix proteins such as collagen type II and aggrecan [6] [7] [8] .
The use of TGF-β, however, revealed contradictory findings and undesired off target effects on the synthesis and functionality of cartilage matrix components. In fact, during chondrogenesis release of high levels of TGF-β may drive progenitor cells to become hypertrophic or induce fibrosis [9, 10] .
The presence of TGF-β during chondrocyte proliferation may be detrimental for the redifferentiation process and may promote the rapid and undesirable differentiation into fibroblast-like cells [11] . Additionally, recent studies have demonstrated that TGF-β signaling plays a critical role in chondrocytes, MSCs and synovial lining cells during the development and progression of osteoarthritis (OA), one of the most common joint diseases [12] . This emerging body of evidence has stimulated researchers to pay special attention to feasible alternatives, including inhibition of specific TGF-β signaling pathways, to achieve sustained and long-term repair, or reduce degeneration of articular cartilage [9, [13] [14] [15] [16] .
Alternatively, cartilage regeneration protocols may rely on deploying morphogenetic signals of developmental pathways or removing potentially anti-chondrogenic factors. As part of this effort, we previously demonstrated that silencing of two anti-chondrogenic regulators, Slug transcription factor and miR-221, induced the expression of chondrogenic markers in hMSCs cultured in monolayer without TGF-β [17] . This prompted us to investigate whether these silenced cells, when properly organized in a three-dimensional environment, could be suitable to trigger the repair process of damaged cartilage tissue in vivo. The aim of this study was to evaluate the chondrogenic potential of miR-221 silenced hMSCs in a three dimensional environment, without exposure to chondrogenic induction media containing TGF-β. The efficacy of miR-221 depletion to induce neocartilage formation and prevent terminal differentiation was investigated in conventional 3D in vitro culture and in an in vivo system represented by a well-established osteochondral culture model [18] [19] [20] . The experimental approach based on miR-221 silencing is in accordance with recent literature demonstrating the effectiveness of the direct targeting of chondrogenic regulators to induce cartilage repair or prevent cartilage degeneration [21] [22] [23] [24] [25] [26] .
We found that silencing of miR-221 promoted chondrogenesis in 3D pellets cultured without TGF-β, a condition that normally does not lead to cartilage formation. Moreover, we demonstrated that miR-221 depleted hMSCs guided the formation of cartilage tissue in vivo, and had a reduced tendency to undergo terminal differentiation. This demonstrates that miR-221 silencing can be sufficient to promote chondrogenesis of hMSCs in vitro and in vivo, thereby having potential for therapeutic applications.
MATERIALS AND METHODS
hMSCs cultures hMSCs were isolated from two sources, Wharton's jelly of umbilical cords and bone marrow.
Human umbilical cords (all from natural deliveries) were collected after mothers' consent and approval of the Ethics Committee of the University of Ferrara and S. Anna Hospital (protocol approved on November 19, 2006) . Harvesting procedures of Wharton's jelly from umbilical cord were conducted in full accordance with the Declaration of Helsinki, as adopted by the 18th World Medical Assembly in 1964 and successively revised in Edinburgh (2000) , and the Good Clinical Practice guidelines. Cords were processed within 4 hours and stored in sterile saline until use [27] .
Typically, the cord was rinsed several times with sterile phosphate-buffered saline (PBS) before processing and cut into pieces (2-4 cm in length). Blood and clots were drained from vessels with PBS to avoid any contamination. Single pieces were dissected, after separating the epithelium of each section along its length, to expose the underlying Wharton's jelly. Subsequently, cord vessels were pulled away and the soft gel tissue was finely chopped. The same tissue (2-3 mm 2 pieces) was placed directly into 75 cm 2 flasks in expansion medium (10% Fetal Calf Serum (Euroclone S.p.A., Milan, Italy), Dulbecco's Modified Eagle's Medium (DMEM) low-glucose supplemented with 100 µg/mL penicillin and 10 µg/mL streptomycin), at 37°C in a humidified atmosphere of 5% CO 2 .
After 5-7 days, the culture medium was removed and then changed twice a week. At subconfluence, cells were trypsinized, and thereafter expanded and used at passage 3 or 4 for in vitro experiments of pellet culture.
hMSCs from bone marrow were obtained from femoral biopsies of donors (age 50-78 years) undergoing total hip replacement, after signed informed consent and with approval of the local bovine serum albumin, 100 nM dexamethasone, 50 µg/ml ascorbate-2 phosphate, 1 mM sodium pyruvate, 100 µg/mL penicillin and 10 µg/mL streptomycin (Sigma-Aldrich), in the absence of conventional chondrogenic inducers (TGF-β). Simultaneously, untransfected hMSCs were cultured as pellets as described above, with or without 10 ng/mL TGF-β3 (Miltenyi, Bergisch, Gladbach, Germany): these conditions were named "TGF-β" and "untreated", respectively. All pellet cultures were maintained at 37°C, 5% CO 2 up to 21 days and the medium was refreshed twice a week. At the chosen time-points (see Fig. 1A ), pellets were either disrupted with a pellet pestle and processed for RNA isolation or fixed in 4% PFA, embedded in paraffin, sectioned and processed for immunohistochemistry.
Osteochondral culture model
Osteochondral defects were created in bovine osteochondral biopsies, as previously described by de Vries-van Melle and colleagues [19] . Osteochondral biopsies that were 8 mm in diameter and 5 mm in length were produced using a diamond-coated trephine drill (Synthes, Oberdorf, Switzerland) from the four proximal sesamoid bones of fresh metacarpal phalangeal joints of 3 to 8 month-old calves. Biopsies were incubated overnight in 10% Fetal Calf Serum DMEM high-glucose supplemented with 1.5 µg/mL fungizone and 50 µg/mL gentamicin to verify sterility. Using a 6 mm-diameter dermal biopsy punch (Stiefel Laboratories, Durham, NC, USA) and a scalpel, osteochondral defects were created: the cartilage and calcified cartilage layers were removed completely and parts of the subchondral bone were damaged by scraping the surface with the scalpel. To prevent outgrowth of cells from the subchondral bone, biopsies were placed in 2% lowgelling agarose (gelling temperature 37-39°C; Eurogentec, Liege, Belgium) in physiological saline solution, in such a way that the subchondral bone was surrounded by the agarose and the cartilage was above the agarose surface.
Culture of hMSCs in the osteochondral model in vitro
To combine the use of transfected hMSCs with the osteochondral model, a specific protocol was optimized. Monolayered hMSCs from bone marrow of three different donors were transfected with antagomiR-221 or antagomiR-Scr as described above, then trypsinized at day 7 and resuspended in 
Statistical analysis
The normal distribution of data was verified using the Kolmogorov-Smirnov test. 
RESULTS

miR-221 silenced hMSCs Spontaneously Undergo Chondrogenic Differentiation in Pellet Culture
The effect of miR-221 silencing on chondrogenic potential was evaluated in pellets formed by hMSCs from Wharton's jelly in the absence of the chondrogenic inducer TGF-β for 21 days (Fig.   1A ). We confirmed here the previous evidence about the downregulation of miR-221 by TGF-β [17] ( Fig. 1B) . Interestingly, antagomiR-221 treatment was highly effective in miR-221 knockdown up to 14 days of pellet culture, achieving >95% inhibition of miR-221 expression with respect to untreated cells. After 21 days of pellet culture, the effect of antagomiR-221 was still appreciable (~60% silencing), with a residual level of miR-221 comparable to the TGF-β treated cells. This evidence allowed us to compare the effects of two different stimuli that lead to a comparable down-regulation of miR-221 expression. Considering that miR-221 is a paralog of miR-222, the effect of antagomiR-221 on miR-222 levels was also evaluated (Fig. S1 ). Before pellet formation (day 0), we observed a significant down-regulation of miR-222 by antagomiR-221 treatment. However, the residual levels of miR-222 were higher than those of miR-221, with a ~450-fold difference (4.51% vs 0.01%). At day 7 of pellet culture, the expression of miR-222, unlike miR-221, was strongly recovered (38.41% vs 1.46%), while at day 21 miR-222 was unaffected by antagomiR-221 treatment (Fig. S1 ). Overall, these data indicate that the effects due to a long exposure to the treatment can be mainly attributed to the silencing of miR-221.
Histological analysis performed on sections from day-21 pellets revealed a comparable positive staining for collagen type II in the antagomiR-221 treated and TGF-β treated cells, (Fig. 2A) , and, accordingly, a strong Alcian Blue staining for GAGs (data not shown). Collagen type X was not detectable on immunohistochemistry ( Fig. 2A) nor on mRNA expression (data not shown),
indicating that these cells in the pellets were not prone to undergo hypertrophic differentiation.
Notably, antagomiR-221 treatment was more effective than TGF-β in inducing the expression of the pro-chondrogenic Sox9 and TRPS1 transcription factors (Fig. 2B ) [8] . In agreement with previous data [17] , antagomiR-221 treatment, unlike TGF-β, maintained Slug protein at very low levels, a favorable condition for the chondrogenic process (Fig. 2B) . These results indicate that miR-221 silencing in hMSCs in pellet culture is effective and sufficient to induce chondrogenesis, in the absence of exogenously added growth factors. The effect of antagomiR-221 treatment was also confirmed in hMSCs from bone marrow ( Fig. S2 and S3 
miR-221 silenced hMSCs Are Effective in Regenerating Cartilage in vivo
To validate the anti-chondrogenic role of miR-221 in vivo, hMSCs were cultured in an osteochondral microenvironment represented by a cartilage defect model [18] [19] [20] (Fig. 3A) . We first evaluated whether the osteochondral model could influence cell viability and silencing efficiency, by culturing hMSCs/alginate and hMSCs/alginate/plug constructs in vitro (Fig. 3B) . We showed that After 12 weeks, miR-221 silenced hMSCs generated a tissue characterized by extensive production of glycosaminoglycans, as evidenced by the presence of a large thionine positive area throughout the entire region of the defect (~37% compared to 12% in control condition; Fig. 4A ). This was different from the newly formed tissue localized in small spots observed when untreated hMSCs were used, and the absence of cartilage formation in defects that were filled with alginate without hMSCs (Fig. 4A) . Consistent with these observations, immunohistological analysis revealed a significantly stronger staining for the chondrogenic markers collagen type II (matrix protein), Sox9
and TRPS1 (transcription factors) in the osteochondral defects filled with miR-221 silenced hMSCs, compared to the osteochondral defects filled with untreated hMSCs (Fig. 4B, C and Table 1 ).
The expression of collagen type X was close to detection limit in two out of three hMSCs donors ( Fig. 4D and Table 1 ). These data confirmed the in vitro results, showing again that an increased deposition of collagen type II is not correlated with an increased deposition of collagen type X after antagomiR-221 treatment.
DISCUSSION
Repair of damaged cartilage remains a major clinical challenge that may rely upon the development of innovative technologies, including regenerative strategies based on the use of hMSCs. Different hMSCs application modalities have been described, some in combination with bio-inspired smart biomaterials and growth factors, to provide better targeted tissue regeneration. However, the optimal strategy has not yet been identified. Much remains to be investigated, such as which hMSCs molecular signaling supports chondrogenic potential, and which culture methods improve hMSCs chondrogenic differentiation before implantation. In the present study, we demonstrated that miR-221 depleted hMSCs are able to spontaneously undergo chondrogenesis in pellet culture in vitro and form cartilage in vivo, without requiring growth factor supplementation. We showed that maintaining low levels of a negative factor by silencing is an effective alternative to induce chondrogenic differentiation, compared to standardized procedures primarily based on TGF-β treatment.
In recent years, many researchers are moving to investigate specific sets of culture conditions which attempt to resemble the physiological environment. In the natural milieu, chondrogenesis goes through a complex differentiation program with production of specific matrix components, due to exposure to a combination of factors with a tight spatiotemporal regulation. Previous molecular studies have shown that mesenchymal progenitors can be stimulated to adopt a chondrogenic fate by TGF-βs [5, 6] . We here confirmed our previous observation that one of the effects of TGF-β is the down-regulation of miR-221, but not its complete suppression [17] . Therefore, the prochondrogenic activity of TGF-β may be counteracted by anti-chondrogenic factors such as miR-221, that still persist in the TGF-β enriched environment. Conversely, hMSCs cultured with antagomiR-221 are able to undergo chondrogenesis avoiding the expression of undesired proteins such as Slug or collagen type X. Therefore, our findings suggested the silencing of miR-221 as a new tool to repair a cartilage defect.
We used an in vivo approach with subcutaneous implantation in mice of a recently developed osteochondral defect model [18] [19] [20] . This tool proved the enhanced potential of engineered hMSCs to regenerate articular cartilage in a microenvironment similar to that found in damaged cartilage.
Previously, implantation of osteochondral biopsies containing hMSCs in osteochondral defects demonstrated the importance of the subchondral bone for the synthesis of cartilage repair tissue, and the contribution of soluble factors others than those of the TGF-β family [18] [19] [20] . In the present work, the results obtained in vitro were validated by the in vivo experiments. Indeed, implantation of osteochondral biopsies with miR-221 silenced hMSCs resulted in significantly more cartilaginous repair tissue compared to the use of non-engineered hMSCs. miR-221 depleted hMSCs promoted a differentiation program that led to the expression of genes required for hyaline chondrogenesis, such as collagen type II and the transcription factors Sox9 and TRPS1. Moreover, one of the most interesting aspect of our results was the observation that the newly formed in vivo tissue was characterized by an ECM that was negative for collagen type X. It is well known that the expression of collagen type X, a marker for chondrocyte hypertrophy and apoptotic death, is an undesired outcome, and remains an unresolved issue in the cell-based approach for cartilage regeneration [29, 30] . Therefore, the ability of miR-221 depleted hMSCs to downregulate collagen It is important to underline that silencing experiments in pellet cultures were here conducted initially with hMSCs from Wharton's jelly, to validate our hypothesis with the same cell source previously used in monolayer culture [17] . Due to the need for a higher number of cells for the in vivo experiments, we then moved to the use of hMSCs from bone marrow. By doing so, we further confirmed the pro-chondrogenic effect of miR-221 silencing, and we also showed that antagomiR-221 treatment was able to induce the expression of the cartilage ECM protein lubricin [31] . In general, the use of hMSCs from different sources allowed us to prove the validity of our hypothesis, concerning the key role of miR-221 as an anti-chondrogenic factor involved in a common regulatory pathway associated with cell fate.
Currently, validated data on the role and mechanism of action of miR-221 during the chondrogenic process, as well as in diseased cartilage, are limited. Putative targets of miR-221 have been recently proposed by a miRNA signature which regulates the chondrogenic mechanism in unrestricted somatic stem cells [32] . miR-221 has been also postulated to be a mechanically responsive miRNA in chondrocytes, being highly expressed in weight bearing compared with non-weight bearing regions of bovine articular cartilage [33, 34] . Moreover, miR-221 expression has been correlated with age, and its low levels have been associated with an increase in phosphatidylinositol 3-kinase signaling, a pathway shown to be implicated in OA [35] .
Within the group of the main predicted and experimentally validated targets of miR-221 and its paralog miR-222, we highlighted the genes known to have a role in cartilage-related pathways, and thus worth pursuing as potential miR-221/222 chondro-targets (Table S1 ). These two miRNAs are encoded by a gene cluster, have the same seed sequence and thus share common predicted target genes. miR-221, as many other miRNAs, can control cellular differentiation and may function through different mechanisms depending on the tissue microenvironment. Therefore, it is not surprising that the list in Table S1 includes genes such as TIMP, FOXO3, DKK2, DVL2, MEOX2, PGC1, SEMA3B, STMN1, MDM2, TRPS1, RECK, ICAM1, FOS, DICER1, ETS1, and ESR1
(references reported in Table S1 ), which are involved in chondrogenesis and cartilage biology.
Among these genes, only cyclin-dependent kinase inhibitor 1B (p27) and mouse double-minute 2 homolog (MDM2) have been experimentally validated as relevant miR-221 chondro-targets [36, 37] . In fact, in bovine cartilage and isolated chondrocytes, Yang and coauthors demonstrated that miR-221 mimic suppressed the expression of p27 leading to the stimulation of chondrocyte proliferation [36] . Down-modulation of MDM2 by miR-221 prevented the degradation of Slug protein, which negatively regulates the proliferation of chondroprogenitors during chondrogenesis of chick limb mesenchymal cells [37] . Consistent with this last evidence, we demonstrated here a very low level of Slug protein in antagomiR-221 treated hMSC cultures, supporting the hypothesis that miR-221 may act through MDM2 to prevent cartilage ECM synthesis.
Hypothesized mechanisms for miR-221 action in the chondrogenic process have been illustrated in Fig. 5 and S4. We suggest that antagomiR-221 treatment promotes chondrogenic processes since it leads to a weakening of the negative control that Slug exerts on chondrogenic factors, such as Sox9 and TRPS1, and cartilage ECM proteins, such as collagen type II and aggrecan (Fig. 5) . Although
Slug is not a direct target of miR-221 [17] , it might act as an effector in a circuit that we hypothesize to end with a reciprocal negative regulation between TRPS1 and miR-221.
Accordingly, we demonstrated here an increase in TRPS1 expression after miR-221 depletion and, previously, the ability of TRPS1 to strongly inhibit miR-221 expression [17] . Since TRPS1 acts as a repressor of Runx2 function [38] , the increased TRPS1 expression may contribute to repress the Runx2-mediated transactivation of genes associated with cartilage hypertrophy and ECM degradation, such as collagen type X, alkaline phosphatase (ALP) and matrix metalloproteinases (MMPs).
It is also conceivable that Sox9, collagen type II and aggrecan are direct miR-221 targets. These genes do not show sequences homologous to miR-221 seed region in their 3'-UTR. However, increasing evidence demonstrates that targeting can also be mediated through sites others than the 3'-UTR, and that seed region base pairing is not necessarily required [39] . Accordingly, a highthroughput screening of a human 3'-UTR library has recently shown that Sox9 is indeed a candidate target gene of miR-221 [40] . In addition, the roles of TGF and Wnt signaling in regulating cell fate during differentiation [41, 9] suggest other scenarios possibly correlated with miR-221 action (Fig.   S4 ). Specific modulation of those factors lead to the production of a stable cartilage phenotype, where hypertrophy is repressed. In light of the results herein reported, we postulate that molecules involved in the TGF/Wnt pathways and regulators of cell cycle and proliferation might be targets of miR-221, thereby affecting the cell fate and the ECM produced by the chondrocytes (Fig. S4 ).
Novel insight onto the mechanisms by which miR-221 works and its interplay with regulatory networks may come from microarray analysis and non-invasive technologies, such as in vivo molecular imaging, that could be applied to our model [42, 43] . In this perspective, our results demonstrating for the first time the critical role of miR-221 in the control of chondrogenesis in vivo, strengthens the need to further investigate miR-221 targets, and offers a new model to apply the aforementioned techniques. We are aware that the demonstration of the effectiveness of silencing anti-chondrogenic factors in MSCs for cartilage repair, does not solve the challenges of creating an environment conducive for long term tissue survival, or restoring functional cartilage. For this purpose, future experiments will also be aimed at assessing the mechanical properties of our constructs, to better define the quality of neo-cartilage that has been formed following the approach herein described. In any case, our results provide a proof of concept for developing experiments which would allow measurement of function restoration, using large animal models of critical size osteochondral defects.
CONCLUSIONS
The work outlined above demonstrates the effectiveness of an innovative approach based on transient transfection of an antagomiRNA as a non-integrative means of direct lineage differentiation. In addition to demonstrating that the expression of miR-221 is a hindrance or major delayer of chondrogenic differentiation, this study showed how knockdown of this molecular regulator is sufficient to enable hMSCs to repair an osteochondral defect.
More generally, the modulation of endogenous molecular cues in directed differentiation strategies will enable greater efficiency and leverage in the generation of target cell types for basic research and regenerative medicine applications. hMSCs/alginate/plug constructs were implanted subcutaneously in nude mice as duplicate samples (two mice per donor, three donors), as outlined in the implantation scheme. After 12 weeks, the constructs were harvested and processed for histological characterization. In case of donor 3, the constructs could be retrieved from one animal only as the second one had to be sacrificed early due to illness. 
